Von Willebrand Disease Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates

DelveInsight's "Von Willebrand Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Von Willebrand Disease, historical and forecasted epidemiology as well as the Von Willebrand Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Von Willebrand Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Von Willebrand Disease Market Forecast
https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Von Willebrand Disease Market Report:
• The Von Willebrand Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In September 2025, The U.S. Food and Drug Administration (FDA) has broadened the approval of recombinant von Willebrand factor (VWF), marketed as Vonvendi, to now include routine preventive treatment for adults with all types of von Willebrand disease (VWD), as well as on-demand bleeding management and perioperative use in pediatric patients with VWD.
• In February 2025, Hemab Therapeutics, a clinical-stage biotechnology company focused on developing innovative prophylactic treatments for severe bleeding and thrombotic disorders, today announced that the first participant with Von Willebrand Disease (VWD) has been administered HMB-002 in the Velora Pioneer Phase 1/2 clinical trial, investigating it as a potential first-in-class subcutaneous therapy for VWD.
• In December 2024, Star Therapeutics, a clinical-stage biotechnology company focused on developing best-in-class antibodies, today shared interim clinical data from VIVID 2, a Phase 1 single ascending dose (SAD) study of VGA039 in patients with Von Willebrand Disease (VWD). VGA039 is an investigational monoclonal antibody targeting Protein S to restore blood clotting balance, serving as a universal hemostatic therapy for various bleeding disorders. It has the potential to become the first subcutaneous treatment for all types of VWD, offering a convenient dosing regimen.
• In April 2024, Octapharma USA, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate®, a lyophilized powder of von Willebrand Factor/Coagulation Factor VIII Complex (Human) for intravenous injection. This approval is specifically for routine prophylaxis aimed at reducing the frequency of bleeding episodes in adults and children aged 6 and older who have von Willebrand disease (VWD).
• In 2023, the total diagnosed prevalent cases of von Willebrand disease in the US were around 13,000, with projections indicating an increase throughout the study period (2020-2034).
• In 2023, females made up approximately 55% of the diagnosed prevalent cases of von Willebrand disease in the US, representing over 7,000 cases.
• In 2023, the 5-13 and 14-18 age groups accounted for approximately 32% and 22% of all diagnosed prevalent cases of von Willebrand disease in the US. The 0-4, 19-44, and over 45 age groups represented around 6%, 23%, and 17% of cases, respectively.
• In 2023, Type 2 and Type 3 von Willebrand disease constituted approximately 11% and 6% of all diagnosed cases in the US, respectively. In contrast, Type 1 von Willebrand disease accounted for about 83% of cases alone.
• Key Von Willebrand Disease Companies: Octapharma, Grifols Therapeutics LLC, CSL Behring, Margaret Ragni, Shire, Archemix Corp., and others
• Key Von Willebrand Disease Therapies: Wilate, plasma-derived FVIII/VWF concentrate, Biostate®, Voncento, Oprelvekin, Interleukin 11, IL-11, Alphanate SD/HT, rVWF, ARC1779, and others
• The Von Willebrand Disease epidemiology based on gender analyzed that females are affected more as compared to males, in case of Von Willebrand disease (VWD)
• The Von Willebrand Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Von Willebrand Disease pipeline products will significantly revolutionize the Von Willebrand Disease market dynamics.

Von Willebrand Disease Overview
Von Willebrand disease (VWD) is a genetic blood disorder characterized by a deficiency or dysfunction of von Willebrand factor (VWF), a protein involved in blood clotting. VWF helps platelets stick together and adhere to blood vessel walls, promoting clot formation and preventing excessive bleeding.

Get a Free sample for the Von Willebrand Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Von Willebrand Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Von Willebrand Disease Epidemiology Segmentation:
The Von Willebrand Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Von Willebrand Disease
• Prevalent Cases of Von Willebrand Disease by severity
• Gender-specific Prevalence of Von Willebrand Disease
• Diagnosed Cases of Episodic and Chronic Von Willebrand Disease

Download the report to understand which factors are driving Von Willebrand Disease epidemiology trends @ Von Willebrand Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Von Willebrand Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Von Willebrand Disease market or expected to get launched during the study period. The analysis covers Von Willebrand Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Von Willebrand Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Von Willebrand Disease Therapies and Key Companies
• Wilate: Octapharma
• plasma-derived FVIII/VWF concentrate: Grifols Therapeutics LLC
• Biostate®: CSL Behring
• Voncento: CSL Behring
• Oprelvekin, Interleukin 11, IL-11: Margaret Ragni
• Alphanate SD/HT: Grifols Biologicals, LLC
• rVWF: Baxalta now part of Shire
• ARC1779: Archemix Corp.

Discover more about therapies set to grab major Von Willebrand Disease market share @ Von Willebrand Disease Treatment Landscape
https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Von Willebrand Disease Market Drivers
• Rise in Von Willebrand Disease (VWD) market is attributed to several factors such as increasing prevalence, evolving research, more diagnostic tests, and novel systemic therapies.

Von Willebrand Disease Market Barriers
• Due to lack of competitors in Von Willebrand Disease, there is a substantial market opportunity for key players to develop Von Willebrand Diseasetargeting therapies.

Scope of the Von Willebrand Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Von Willebrand Disease Companies: Octapharma, Grifols Therapeutics LLC, CSL Behring, Margaret Ragni, Shire, Archemix Corp., and others
• Key Von Willebrand Disease Therapies: Wilate, plasma-derived FVIII/VWF concentrate, Biostate®, Voncento, Oprelvekin, Interleukin 11, IL-11, Alphanate SD/HT, rVWF, ARC1779, and others
• Von Willebrand Disease Therapeutic Assessment: Von Willebrand Disease current marketed and Von Willebrand Disease emerging therapies
• Von Willebrand Disease Market Dynamics: Von Willebrand Disease market drivers and Von Willebrand Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Von Willebrand Disease Unmet Needs, KOL's views, Analyst's views, Von Willebrand Disease Market Access and Reimbursement

To know more about Von Willebrand Disease companies working in the treatment market, visit @ Von Willebrand Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.